As the main ligand of PD-1, PD-L1 is currently recognized as a negative immunoregulatory protein and is highly expressed in many malignant tumors, including NSCLC [6, 7], melanoma [8], renal cell carcinoma [9], prostate cancer [10], breast cancer [11]. Here, CD274 is linked to non-small cell lung carcinoma.